Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 64

1.

Heterogeneity of treatment effects: implications for guidelines, payment, and quality assessment.

Greenfield S, Kravitz R, Duan N, Kaplan SH.

Am J Med. 2007 Apr;120(4 Suppl 1):S3-9. Review.

PMID:
17403380
2.

Curbing the cardiovascular disease epidemic: aligning industry, government, payers, and academics.

Califf RM, Harrington RA, Madre LK, Peterson ED, Roth D, Schulman KA.

Health Aff (Millwood). 2007 Jan-Feb;26(1):62-74.

PMID:
17211015
3.

Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?

Harrington RA, Califf RM.

J Am Coll Cardiol. 2006 Dec 19;48(12):2592-5. Epub 2006 Oct 31. No abstract available.

4.

Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.

Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C; BASKET-LATE Investigators.

J Am Coll Cardiol. 2006 Dec 19;48(12):2584-91. Epub 2006 Nov 2.

5.

Correction of anemia with epoetin alfa in chronic kidney disease.

Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators.

N Engl J Med. 2006 Nov 16;355(20):2085-98.

6.

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR.

Lancet. 2006 Sep 23;368(9541):1096-105. Erratum in: Lancet. 2006 Nov 18;368(9549):1770.

7.

Priorities among effective clinical preventive services: methods.

Maciosek MV, Edwards NM, Coffield AB, Flottemesch TJ, Nelson WW, Goodman MJ, Solberg LI.

Am J Prev Med. 2006 Jul;31(1):90-6. Review.

PMID:
16777547
8.

The challenge of subgroup analyses--reporting without distorting.

Lagakos SW.

N Engl J Med. 2006 Apr 20;354(16):1667-9. No abstract available. Erratum in: N Engl J Med. 2006 Aug 3;355(5):533.

PMID:
16625007
9.

Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis.

Hayward RA, Kent DM, Vijan S, Hofer TP.

BMC Med Res Methodol. 2006 Apr 13;6:18.

10.

Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above?

Califf RM.

JAMA. 2006 Apr 5;295(13):1579-80. Epub 2006 Mar 14. No abstract available.

PMID:
16537724
11.

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators.

N Engl J Med. 2006 Apr 20;354(16):1706-17. Epub 2006 Mar 12.

12.

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.

Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.

JAMA. 2005 Nov 16;294(19):2437-45. Erratum in: JAMA. 2005 Dec 28;294(24):3092.

PMID:
16287954
13.

Reporting clinical trial results to inform providers, payers, and consumers.

Hayward RA, Kent DM, Vijan S, Hofer TP.

Health Aff (Millwood). 2005 Nov-Dec;24(6):1571-81.

PMID:
16284031
14.

Bayesian predictions of final outcomes: regulatory approval of a spinal implant.

Lipscomb B, Ma G, Berry DA.

Clin Trials. 2005;2(4):325-33; discussion 334-9, 364-78.

PMID:
16281431
15.

Optimal timing of intervention in non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) Registry.

Ryan JW, Peterson ED, Chen AY, Roe MT, Ohman EM, Cannon CP, Berger PB, Saucedo JF, DeLong ER, Normand SL, Pollack CV Jr, Cohen DJ; CRUSADE Investigators.

Circulation. 2005 Nov 15;112(20):3049-57. Epub 2005 Nov 7.

16.

Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials.

Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G, Califf RM.

JAMA. 2005 Oct 5;294(13):1664-70.

PMID:
16204666
17.

Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial.

Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW; ESCAPE Investigators and ESCAPE Study Coordinators.

JAMA. 2005 Oct 5;294(13):1625-33.

PMID:
16204662
18.

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

19.

Evidence synthesis and evidence-based decision making: related but distinct processes.

Teutsch SM, Berger ML.

Med Decis Making. 2005 Sep-Oct;25(5):487-9. No abstract available.

PMID:
16160204
20.

Acting on imperfect evidence: How much regret are we ready to accept?

Djulbegovic B, Frohlich A, Bennett CL.

J Clin Oncol. 2005 Oct 1;23(28):6822-5. Epub 2005 Sep 6. No abstract available.

PMID:
16145058

Supplemental Content

Support Center